Oxidant stress and renal function among children with chronic kidney disease: a repeated measures study

Melanie H Jacobson, Mengling Liu, Yinxiang Wu, Susan Furth, Bradley Warady, Howard Trachtman, Leonardo Trasande, Melanie H Jacobson, Mengling Liu, Yinxiang Wu, Susan Furth, Bradley Warady, Howard Trachtman, Leonardo Trasande

Abstract

It is hypothesized that chronic kidney disease (CKD) induces oxidant stress which contributes to the decline in kidney function. However, few studies have incorporated longitudinal designs and no studies have investigated this association among children. Using data from the Chronic Kidney Disease in Children (CKiD) study, we examined longitudinal associations between urinary biomarkers of oxidant stress, 8-OH deoxyguanosine (8-OHdG) and F2-isoprostane, and measures of renal function and blood pressure among children with CKD. Baseline levels of 8-OHdG were positively associated with estimated glomerular filtration rate (eGFR) over time and a log-unit increase in baseline 8-OHdG predicted a 5.68 ml/min/1.73 m2 increase in eGFR (95% Confidence Interval (CI): 3.75, 7.61). This association was attenuated when longitudinal measures of 8-OHdG were analyzed in relation to longitudinal eGFR (per log-unit increase in 8-OHdG, β = 0.81, 95% CI: 0.22, 1.39). Baseline 8-OHdG concentrations were also associated with decreased proteinuria over time, as measured by urinary protein:creatinine ratio. In addition, F2-isoprostane concentrations were associated with increases in eGFR, but only when baseline levels (vs. longitudinal levels) were considered in relation to longitudinal eGFR. There were no significant associations between either 8-OHdG or F2-isoprostane and blood pressure over time. Urinary measures of oxidant stress are not associated with worsening GFR over time. Our findings suggest that excretion of these biomarkers may be influenced by changes in glomerular and tubular function in varying patterns, which would limit their value in evaluating the impact of oxidant stress on CKD progression in children.

Conflict of interest statement

The authors declare no competing interests.

References

    1. Levey AS, Coresh J. Chronic kidney disease. The lancet. 2012;379:165–180. doi: 10.1016/S0140-6736(11)60178-5.
    1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. American Journal of Kidney Diseases. 2003;41:1–12. doi: 10.1053/ajkd.2003.50007.
    1. Levey AS, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of internal medicine. 2003;139:137–147. doi: 10.7326/0003-4819-139-2-200307150-00013.
    1. Hoerger TJ, et al. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative. American Journal of Kidney Diseases. 2015;65:403–411. doi: 10.1053/j.ajkd.2014.09.023.
    1. Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL. CKiD (CKD in children) prospective cohort study: a review of current findings. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2012;60:1002–1011. doi: 10.1053/j.ajkd.2012.07.018.
    1. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. Clinical kidney journal. 2016;9:583–591. doi: 10.1093/ckj/sfw047.
    1. Staples A, Wong C. Risk factors for progression of chronic kidney disease. Current opinion in pediatrics. 2010;22:161. doi: 10.1097/MOP.0b013e328336ebb0.
    1. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti‐oxidant therapies and chronic kidney disease. Nephrology. 2012;17:311–321. doi: 10.1111/j.1440-1797.2012.01572.x.
    1. Okamura DM, Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatric nephrology. 2009;24:2309. doi: 10.1007/s00467-009-1199-5.
    1. Schrier RW, Harris DC, Chan L, Shapiro JI, Caramelo C. Tubular hypermetabolism as a factor in the progression of chronic renal failure. American journal of kidney diseases: the official journal of the National Kidney Foundation. 1988;12:243–249. doi: 10.1016/S0272-6386(88)80130-6.
    1. Vaziri ND, Rodríguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nature Reviews Nephrology. 2006;2:582.
    1. Li L, et al. High Salt Enhances Reactive Oxygen Species and Angiotensin II Contractions of Glomerular Afferent Arterioles From Mice With Reduced Renal Mass. Hypertension. 2018;72:1208–1216. doi: 10.1161/HYPERTENSIONAHA.118.11354.
    1. Oberg BP, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney international. 2004;65:1009–1016. doi: 10.1111/j.1523-1755.2004.00465.x.
    1. Karamouzis I, et al. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. American journal of nephrology. 2008;28:397–404. doi: 10.1159/000112413.
    1. Dounousi E, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. American Journal of Kidney Diseases. 2006;48:752–760. doi: 10.1053/j.ajkd.2006.08.015.
    1. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2005;10(Suppl 1):S10–23. doi: 10.1080/13547500500216546.
    1. Roberts LJ, II, Morrow JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radical Biology and Medicine. 2000;28:505–513. doi: 10.1016/S0891-5849(99)00264-6.
    1. Wu LL, Chiou C-C, Chang P-Y, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clinica Chimica Acta. 2004;339:1–9. doi: 10.1016/j.cccn.2003.09.010.
    1. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? British journal of pharmacology. 2004;142:231–255. doi: 10.1038/sj.bjp.0705776.
    1. Furth SL, et al. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clinical Journal of the American Society of Nephrology. 2006;1:1006–1015. doi: 10.2215/CJN.01941205.
    1. Hornung RW, Reed LD. Estimation of average concentration in the presence of nondetectable values. Applied occupational and environmental hygiene. 1990;5:46–51. doi: 10.1080/1047322X.1990.10389587.
    1. Wong CS, et al. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clinical Journal of the American Society of Nephrology. 2009;4:812–819. doi: 10.2215/CJN.01780408.
    1. Schwartz GJ, et al. New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology: JASN. 2009;20:629–637. doi: 10.1681/asn.2008030287.
    1. Flynn JT, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension (Dallas, Tex.: 1979) 2008;52:631–637. doi: 10.1161/HYPERTENSIONAHA.108.110635.
    1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–576. doi: 10.1542/peds.114.2.S2.555.
    1. Warady BA, et al. Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2015;65:878–888. doi: 10.1053/j.ajkd.2015.01.008.
    1. Kleinbaum, D. & Klein, M. J. N. Y. Springer-Verlag. Survival Analysis: A self-learning text, 2005 (2011).
    1. Barr DB, et al. Urinary creatinine concentrations in the US population: implications for urinary biologic monitoring measurements. Environmental health perspectives. 2004;113:192–200. doi: 10.1289/ehp.7337.
    1. Weaver VM, Kotchmar DJ, Fadrowski JJ, Silbergeld EK. Challenges for environmental epidemiology research: are biomarker concentrations altered by kidney function or urine concentration adjustment? Journal of Exposure Science and Environmental Epidemiology. 2016;26:1. doi: 10.1038/jes.2015.8.
    1. Wright J, et al. Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney DiseaseResults From the AASK Trial. JAMA. 2002;288:2421–2431. doi: 10.1001/jama.288.19.2421.
    1. Keaney JF, Jr., et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arteriosclerosis, thrombosis, and vascular biology. 2003;23:434–439. doi: 10.1161/01.ATV.0000058402.34138.11.
    1. Tamura S, et al. Evaluation of a urinary multi-parameter biomarker set for oxidative stress in children, adolescents and young adults. Free radical research. 2006;40:1198–1205. doi: 10.1080/10715760600895191.
    1. Kosecik M, Erel O, Sevinc E, Selek S. Increased oxidative stress in children exposed to passive smoking. International journal of cardiology. 2005;100:61–64. doi: 10.1016/j.ijcard.2004.05.069.
    1. Fathallah-Shaykh SA, et al. Progression of Pediatric CKD of Nonglomerular Origin in the CKiD Cohort. Clinical Journal of the American Society of Nephrology. 2015;10:571–577. doi: 10.2215/cjn.07480714.
    1. Feairheller DL, et al. Racial differences in oxidative stress and inflammation: in vitro and in vivo. Clinical and translational science. 2011;4:32–37. doi: 10.1111/j.1752-8062.2011.00264.x.
    1. Luo S, et al. Serum Metabolomic Alterations Associated with Proteinuria in CKD. Clinical Journal of the American Society of Nephrology. 2019;14:342–353. doi: 10.2215/CJN.10010818.
    1. Abdelmalek JA, Gansevoort RT, Heerspink HJL, Ix JH, Rifkin DE. Estimated albumin excretion rate versus urine albumin-creatinine ratio for the assessment of albuminuria: a diagnostic test study from the Prevention of Renal and Vascular Endstage Disease (PREVEND) Study. American Journal of Kidney Diseases. 2014;63:415–421. doi: 10.1053/j.ajkd.2013.10.061.
    1. Ix JH, et al. Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clinical Journal of the American Society of Nephrology. 2011;6:184–191. doi: 10.2215/CJN.05030610.
    1. [No authors listed]. Chapter 1: Definition and classification of CKD. Kidney international supplements3, 19–62, 10.1038/kisup.2012.64 (2013).
    1. Himmelfarb J, et al. Oxidative stress is increased in critically ill patients with acute renal failure. Journal of the American Society of Nephrology. 2004;15:2449–2456. doi: 10.1097/01.ASN.0000138232.68452.3B.
    1. Simmons EM, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation. 2005;79:914–919. doi: 10.1097/01.TP.0000157773.96534.29.
    1. Dhingra R, Winquist A, Darrow LA, Klein M, Steenland K. A study of reverse causation: Examining the associations of perfluorooctanoic acid serum levels with two outcomes. Environmental health perspectives. 2016;125:416–421. doi: 10.1289/EHP273.
    1. Watkins DJ, et al. Exposure to perfluoroalkyl acids and markers of kidney function among children and adolescents living near a chemical plant. Environmental health perspectives. 2013;121:625–630. doi: 10.1289/ehp.1205838.
    1. Longnecker MP. Pharmacokinetic variability and the miracle of modern analytical chemistry. Epidemiology. 2006;17:350–351. doi: 10.1097/01.ede.0000222510.59457.7b.
    1. Dorne J, Renwick AG. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicological Sciences. 2005;86:20–26. doi: 10.1093/toxsci/kfi160.
    1. Nerpin, E. et al. Inflammation, oxidative stress, glomerular filtration rate, and albuminuria in elderly men: a cross-sectional study. 5, 537, 10.1186/1756-0500-5-537 (2012).
    1. Upadhyay A, et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2011;26:920–926. doi: 10.1093/ndt/gfq471.
    1. Sauriasari R, Wulandari F, Nurifahmi R, Sekar AP, Susilo VY. The Correlation Between Urinary 8-Iso-Prostaglandin F2alpha and Hydrogen Peroxide Toward Renal Function in T2DM Patients Consuming Sulfonylurea and Combination of Metformin-Sulfonylurea. Current diabetes reviews. 2018;14:189–195. doi: 10.2174/1573399812666161214141716.
    1. Schei J, et al. Urinary Markers of Oxidative Stress Are Associated With Albuminuria But Not GFR Decline. Kidney International Reports. 2018;3:573–582. doi: 10.1016/j.ekir.2017.11.020.
    1. Nourooz-Zadeh Jaffar. Key issues in F2-isoprostane analysis. Biochemical Society Transactions. 2008;36(5):1060–1065. doi: 10.1042/BST0361060.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel